Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL292856 | 1.00 | LMNA (0.60) | LMNAALDH1A1TSHRTDP1CA4 | |
| Acetone SCHEMBL1831044 | 1.00 | LMNA (0.60) | LMNAALDH1A1TSHRTDP1CA4 | |
| Acetone SCHEMBL100424 | 1.00 | — | — | |
| Acetone SCHEMBL6859028 | 1.00 | LMNA (0.60) | LMNAALDH1A1TSHRTDP1CA4 | |
| Acetone SCHEMBL9217023 | 1.00 | LMNA (0.60) | LMNAALDH1A1TSHRTDP1CA4 | |
| Acetone SCHEMBL9324675 | 1.00 | LMNA (0.60) | LMNAALDH1A1TSHRTDP1CA4 | |
| Acetone SCHEMBL6859109 | 1.00 | LMNA (0.60) | LMNAALDH1A1TSHRTDP1CA4 | |
| Acetone SCHEMBL4095931 | 1.00 | LMNA (0.60) | LMNAALDH1A1TSHRTDP1CA4 | |
| Acetone SCHEMBL6859386 | 1.00 | LMNA (0.60) | LMNAALDH1A1TSHRTDP1CA4 | |
| Acetone SCHEMBL9723202 | 1.00 | LMNA (0.60) | LMNAALDH1A1TSHRTDP1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183959-A1 | P38 KINASE INHIBITING AGENTS | CHEN MENG-HSIN | 2011-07-28 | — | — | US | disclosed |
| US-7879875-B2 | such as 6-(2,4-difluorophenyl)-1-[2-fluoro-5-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-2H-quinolizin-2-one, used as antipyretics, analgesics, or in the treatment of arthritis, osteoarthritis, eczema, psoriasis and vision defects | Merk Sharp & Dohme Corp. (US) | 2011-02-01 | — | — | US | disclosed |
| US-5047540-A | Platelet Activating Factor Antagonists and Antitumor Agents | SHIONOGI & CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183959-A1 | P38 KINASE INHIBITING AGENTS | MAPK1, MAPK8, MAPK7 | LMNA 4285/4885ALDH1A1 1400/4885TSHR 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.